Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
Alger Health Sciences A AHSAX
- NAV / 1-Day Return 22.11 / −0.36 %
- Total Assets 112.4 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.130%
- Distribution Fee Level Below Average
- Share Class Type Front Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield —
- Turnover 306%
USD | NAV as of May 23, 2024 | 1-Day Return as of May 23, 2024, 12:47 AM GMT+0
Morningstar’s Analysis AHSAX
Will AHSAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.5
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 5.76 | 6.7 Mil | Healthcare |
Stryker Corp | 4.98 | 5.8 Mil | Healthcare |
Boston Scientific Corp | 4.91 | 5.7 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 4.91 | 5.7 Mil | Healthcare |
Merck & Co Inc | 4.77 | 5.5 Mil | Healthcare |
McKesson Corp | 4.52 | 5.2 Mil | Healthcare |
Intuitive Surgical Inc | 4.15 | 4.8 Mil | Healthcare |
Novo Nordisk A/S ADR | 3.88 | 4.5 Mil | Healthcare |
AbbVie Inc | 3.47 | 4.0 Mil | Healthcare |
Oscar Health Inc Class A | 3.11 | 3.6 Mil | Healthcare |